











Prior Authorization Request Administrative Information

Member Information						
Last name	First name		МІ			
Member ID	Date of birth					
Sex assigned at birth Female Male "X" or Intersex						
Current gender Female Male Transgender male Transgender female Other						
Place of residence						
Race/ethnicity Preferred spoken language Preferred written language						
MassHealth does not exclude people or treat them differently because of race, color, national origin, age, disability, religion, creed, sexual orientation, or sex (including gender identity and gender stereotyping).						
Plan Contact Information						
Please indicate the member's MassHealth Plan according to the Plan's contact information belo		his completed and signed	form			
MassHealth Fee-For-Service (FFS) Plan, Primary Care Clinician (PCC) Plan, Primary Care Accountable Care Organization (PCACO) Plan, Children's Medical Security Plan, and Health Safety Net Plan						
☐ MassHealth Drug Utilization Review Program						
Pharmacy: Fax: (877) 208-7428 - Tel: (800	Pharmacy: Fax: (877) 208-7428 - Tel: (800) 745-7318					
MassHealth Managed Care Organization (MCO) and Accountable Care Partnership Plans (ACPP)						
☐ Fallon Health						
Online Prior Authorization: go.covermymeds.com/OptumRx						
Online Prior Authorization: providerportal.surescripts.net/ProviderPortal/optum						
Pharmacy: Fax: (844) 403-1029 - Tel: (844) 720-0033						
☐ Health New England						
Online Prior Authorization: go.covermymeds.com/OptumRx						
Pharmacy: Fax: (800) 550-9246 - Tel: (800) 918-7545						
☐ Mass General Brigham Health Plan						
Online Prior Authorization (Non-Specialty Drugs): go.covermymeds.com/OptumRx						
Online Prior Authorization (Specialty/Medical Drugs): provider.massgeneralbrighamhealthplan.org						
Pharmacy: Fax: (844) 403-1029 - Tel: (800) 711-4555						
☐ Tufts Health Plan						
Online Prior Authorization: point32health.promptpa.com						
Pharmacy: Fax: (617) 673-0939 - Tel: (888) 257-1985						
☐ WellSense Health Plan						
Online Prior Authorization: wellsense.org/providers/ma/pharmacy/prior-authorizations						
Pharmacy: Fax: (833) 951-1680 - Tel: (877) 417-1822						

Topical Vitamin D Analogues Prior Authorization Request

MassHealth reviews requests for prior authorization (PA) on the basis of medical necessity only. If MassHealth approves the request, payment is still subject to all general conditions of MassHealth, including current member eligibility, other insurance, and program restrictions. MassHealth will notify the requesting provider and member of its decision. Keep a copy of this form for your records. If faxing this form, please use black ink.

Additional information about these agents, including PA requirements and preferred products, can be found within the MassHealth Drug List at www.mass.gov/druglist.

Madigation requested and tube size	Eraguanov of application	
Medication requested and tube size	Frequency of application	
☐ calcipotriene cream (quantity > 60 grams/month)		
60 gram tube 120 gram tube	Indication (Check all that apply, or ICD-10 code,	
calcipotriene foam	if applicable)	
☐ 60 gram tube ☐ 120 gram tube	☐ Plaque psoriasis	
☐ calcipotriene ointment (quantity > 60	Other (Please indicate.)	
grams/month)		
☐ 60 gram tube ☐ 120 gram tube		
calcitriol ointment		
100 gram tube		
Other*		
	Drug NDC (if known) or service code	
preferred product).		
1. Has the member had a trial with a topical corticost		
Has the member had a trial with a topical corticost Yes. Please list the drug name, dates/duration	eroid? of use, and outcome of trial as noted below.*	
Has the member had a trial with a topical corticost Yes. Please list the drug name, dates/duration Drug name	of use, and outcome of trial as noted below.* Dates/duration of use	
Has the member had a trial with a topical corticost Yes. Please list the drug name, dates/duration Drug name Did the member experience any of the following the following trial trial with a topical corticost and the following trial trial with a topical corticost and the following trial trial with a topical corticost and the following trial with th	eroid? of use, and outcome of trial as noted below.* Dates/duration of use g outcomes? Adverse reaction Inadequate response	
Has the member had a trial with a topical corticost Yes. Please list the drug name, dates/duration Drug name	eroid? of use, and outcome of trial as noted below.* Dates/duration of use g outcomes? Adverse reaction Inadequate response	
Has the member had a trial with a topical corticost Yes. Please list the drug name, dates/duration Drug name Did the member experience any of the following the following trial trial with a topical corticost and the following trial trial with a topical corticost and the following trial trial with a topical corticost and the following trial with th	of use, and outcome of trial as noted below.* Dates/duration of use g outcomes? Adverse reaction Inadequate response nadequate response.	
Has the member had a trial with a topical corticost Yes. Please list the drug name, dates/duration Drug name Did the member experience any of the following Briefly describe details of adverse reaction or incomplete.	of use, and outcome of trial as noted below.* Dates/duration of use g outcomes? Adverse reaction Inadequate response nadequate response.	
Has the member had a trial with a topical corticost Yes. Please list the drug name, dates/duration Drug name Did the member experience any of the following Briefly describe details of adverse reaction or incomplete.	eroid? of use, and outcome of trial as noted below.* Dates/duration of use g outcomes? Adverse reaction Inadequate response nadequate response. to topical corticosteroids? Please explain.	
Has the member had a trial with a topical corticost Yes. Please list the drug name, dates/duration Drug name Did the member experience any of the following Briefly describe details of adverse reaction or i No. Does the member have a contraindication	eroid? of use, and outcome of trial as noted below.* Dates/duration of use ag outcomes? Adverse reaction Inadequate response nadequate response. to topical corticosteroids? Please explain. am, ointment, or scalp solution?	
1. Has the member had a trial with a topical corticost Yes. Please list the drug name, dates/duration Drug name Did the member experience any of the following Briefly describe details of adverse reaction or i No. Does the member have a contraindication 2. Has the member had a trial with calcipotriene creation.	eroid? of use, and outcome of trial as noted below.* Dates/duration of use ag outcomes? Adverse reaction Inadequate response nadequate response. to topical corticosteroids? Please explain. am, ointment, or scalp solution?	

PA-60 (Rev. 04/24) over

	Briefly describe details of adverse reaction or inadequate response.
	 No. Does the member have a contraindication to calcipotriene cream, ointment, and scalp solution? Please explain.
*	Please attach a letter documenting additional trials as necessary.
	ection II. Please complete for requests for quantities exceeding established quantity limits. Please describe the clinical rationale for exceeding the quantity limit.
	ection III. Please complete and provide documentation for exceptions to Step Therapy. Is the alternative drug required under the step therapy protocol contraindicated, or will likely cause an adverse reaction in, or physical or mental harm to the member? If yes, briefly describe details of contraindication, adverse reaction, or harm.
2.	Is the alternative drug required under the step therapy protocol expected to be ineffective based on the known clinical characteristics of the member and the known characteristics of the alternative drug regimen? Yes No If yes, briefly describe details of known clinical characteristics of member and alternative drug regimen.
3.	Has the member previously tried the alternative drug required under the step therapy protocol, or another alternative drug in the same pharmacologic class or with the same mechanism of action, and such alternative drug was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event? Yes No If yes, please provide details for the previous trial. Drug name Dates/duration of use Did the member experience any of the following? Adverse reaction Inadequate response Briefly describe details of adverse reaction or inadequate response.
4.	Is the member stable on the requested prescription drug prescribed by the health care provider, and switching drugs will likely cause an adverse reaction in or physical or mental harm to the member? Yes. Please provide details No

Please continue to next page and complete Prescriber and Provider Information section.

Prior Authorization Request Prescriber and Provider Information

Prescriber Information		
Last name*	First name*	MI
NPI*	Individual MH Provide	er ID
DEA No.	Office Contact Name	
Address	City	State Zip
Email address		
Telephone No.*	Fax No.*	
* Required		
Please also complete for professionally	administered medication	ns, if applicable.
Start date	End date	
Servicing prescriber/facility name		☐ Same as prescribing provider
Servicing provider/facility address		
Servicing provider NPI/tax ID No.		
Name of billing provider		
Billing provider NPI No.		
Is this a request for recertification? Yes] No	
CPT code No. of visits	J code	No. of units
Prescribing provider's attestation, signal certify under the pains and penalties of perjoinformation section of this form. Any attached I certify that the medical necessity information complete, to the best of my knowledge. I under prosecution for any falsification, omission, or	ury that I am the prescribing I statement on my letterhead (per 130 CMR 450.204) on erstand that I may be subject concealment of any material	has been reviewed and signed by me. this form is true, accurate, and to civil penalties or criminal I fact contained herein.
Prescribing provider's signature		_
Printed name of prescribing provider (The form can either be signed by hand and		

(The form can either be signed by hand and then scanned, or it can be signed electronically using DocuSign or Adobe Sign. For electronic signatures, the signer can upload a picture of their wet signature. The typed text of a signature is not an acceptable form of an electronic signature.)